Skip to main content

Table 2 Association of clinical and genetic factors with overall survival

From: Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma

Factor Group n Median survival (d) p value
Age (y) > 70 20 660 (413–876) 0.00030
≤ 70 8 333 (105–432)  
Sex Male 17 475 (385–735) 0.39
Female 11 412 (175–841)  
Pre-KPS > 70 16 409 (314–611) 0.060
≤ 70 12 689 (432–881)  
EOR Gross total resection 25 475 (406–689) 0.50
Partial resection 3 432 (105-NA)  
BCNU wafer No 19 660 (381–876) 0.11
Yes 9 441 (149–611)  
Bevacizumab No 20 453.5 (335–674) 0.75
Yes 8 565 (314–881)  
Region 1 Methylated 13 674 (406–876) 0.27
Unmethylated 8 422 (105–881)  
Region 2 Methylated 13 841 (413–961) 0.0026
Unmethylated 8 363 (105–660)  
Region 3 Methylated 3 876 (406-NA) 0.65
Unmethylated 18 521.5 (331–735)  
  1. Pre-KPS Preoperative Karnofsky Performance Status